880 related articles for article (PubMed ID: 17948613)
1. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
2. Current pharmacotherapeutic treatment options in Parkinson's disease.
Rezak M
Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
[TBL] [Abstract][Full Text] [Related]
3. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
4. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
5. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Widnell KL; Comella C
Mov Disord; 2005; 20 Suppl 11():S30-7. PubMed ID: 15822107
[TBL] [Abstract][Full Text] [Related]
6. Issues important for rational COMT inhibition.
Dingemanse J
Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
[TBL] [Abstract][Full Text] [Related]
7. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Kaakkola S
Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
[TBL] [Abstract][Full Text] [Related]
8. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
10. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
Danisi F
Geriatrics; 2002 Mar; 57(3):46-50; quiz 52. PubMed ID: 11899548
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
14. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
Tse W
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
16. Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Ahlskog JE
Mayo Clin Proc; 2014 Jul; 89(7):997-1003. PubMed ID: 24996235
[TBL] [Abstract][Full Text] [Related]
17. Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.
Hauser RA
Geriatrics; 2006 Sep; 61(9):14-20. PubMed ID: 16989543
[TBL] [Abstract][Full Text] [Related]
18. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
19. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Simonson W; Hauser RA; Schapira AH
Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
[TBL] [Abstract][Full Text] [Related]
20. Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC; Hauser RA
Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]